Neoadjuvant chemotherapy combined with interval cytoreductive surgery in ovarian cancer.

Abstract

Administering neoadjuvant chemotherapy combined with interval cytoreductive surgery for patients with advanced ovarian cancer can reduce the operation time, intraoperative blood loss and ascites volume. Besides, the size of residual lesions after cytoreductive surgery, age and FIGO stage are independent factors affecting the postoperative OS of patients.